Capricor Therapeutics, Inc. — Q3 2014 Form 10-Q Summary
Business Context and Reporting Period
Capricor Therapeutics is a development-stage biotechnology company focused primarily on cardiovascular therapies. The company reported unaudited results for the three and nine months ended September 30, 2014. Its six candidates included CAP-1002, CAP-1001, cardiospheres, exosomes, cenderitide and CU-NP. The November 2013 merger with Nile Therapeutics was accounted for as a reverse merger, with Capricor as the accounting acquirer.
CAP-1002 was being evaluated in the Phase I/II ALLSTAR trial, with Phase II enrollment begun in the first quarter of 2014. The company had no product sales and remained dependent on collaborations, grants, debt and future financing.
Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Collaboration income | $1.04 million | $3.13 million |
| Grant income | $0.26 million | $0.26 million |
| Total income | $1.30 million | $3.38 million |
| Research and development expense | $1.97 million | $5.20 million |
| General and administrative expense | $0.82 million | $2.33 million |
| Loss from operations | $(1.49) million | $(4.15) million |
| Net loss | $(1.54) million | $(4.29) million |
| Net loss per share | $(0.13) | $(0.37) |
| Operating cash flow | Not separately reported for the quarter | $3.10 million provided |
Revenue and margin measures are not indicative of commercial operations because the company had no product revenue. Collaboration income primarily represented ratable recognition of the $12.5 million Janssen upfront payment, with recognition subject to continuing performance obligations.
| Balance Sheet Metric | September 30, 2014 | December 31, 2013 |
|---|---|---|
| Cash and cash equivalents | $9.81 million | $1.73 million |
| Marketable securities | $0.33 million | $0.33 million |
| Restricted cash | $3.70 million | $1.40 million |
| Total current assets | $14.20 million | $3.68 million |
| Total liabilities | $20.75 million | $6.07 million |
| Loan payable | $9.16 million | $3.96 million |
| Deferred income | $9.38 million | None reported |
| Stockholders’ equity (deficit) | $(4.47) million | $(0.53) million |
Material Changes Versus the Prior Comparable Period
- Total income increased to $1.30 million from $0.08 million in the third quarter and to $3.38 million from $0.50 million for the nine-month period, primarily because of Janssen collaboration income.
- R&D expense increased approximately 95% in the quarter and 48% for the nine months, driven by CAP-1002 clinical, manufacturing, site and patient costs, DYNAMIC preparation, Janssen collaboration work and increased personnel.
- G&A expense increased approximately $0.2 million in the quarter and $0.8 million for the nine months, reflecting higher legal, recruiting, public-company compliance, headcount and stock-based compensation costs.
- Despite higher operating expenses, net loss modestly improved from $1.55 million to $1.54 million in the quarter and from $4.59 million to $4.29 million for the nine months.
- Operating cash flow improved from $6.32 million used in the prior-year nine-month period to $3.10 million provided, primarily because of the $12.5 million Janssen payment. Financing cash flow included $5.20 million of CIRM loan proceeds.
- Cash and cash equivalents increased by $8.08 million year to date, while restricted cash increased by $2.30 million for ALLSTAR trial costs.
Guidance, Outlook, Risks and Unusual Items
- Management expected to spend approximately $7.0 million to $9.5 million during 2014 on CAP-1002 development, primarily the Phase II ALLSTAR trial, and approximately $0.4 million on cenderitide development in preparation for a planned 2015 Phase I trial.
- The company planned to pursue the DYNAMIC Phase I trial using CAP-1002 and announced plans to explore CAP-1002 for Duchenne muscular dystrophy, subject to regulatory progress. It also planned to commence a cenderitide Phase I trial in the first half of 2015.
- Janssen held an exclusive option to license CAP-1002 and related products after delivery of six-month Phase II ALLSTAR follow-up results. Exercise could provide an upfront fee, milestone payments of up to $325.0 million and royalties, but there was no assurance the option would be exercised.
- The CIRM loan award permits disbursements of up to approximately $19.8 million for ALLSTAR, but repayment with interest and a potential risk premium of up to 500% of the loan amount may apply upon specified revenue thresholds. Disbursements depend on milestones and CIRM funding availability; certain circumstances may permit forgiveness.
- The company stated that substantial additional financing would be required before it could complete development and that it might never achieve profitability. Potential financing could dilute shareholders or impose restrictive debt covenants.
- Key risks include clinical-trial failure or delay, regulatory rejection, manufacturing and donor-tissue constraints, dependence on third-party collaborators and licensors, intellectual-property challenges, competition, limited personnel and manufacturing experience, and uncertain reimbursement or market acceptance.
- On October 8, 2014, after quarter-end, the company acquired certain natriuretic-peptide patent rights from Medtronic for $100,000 upfront, with potential milestone payments of up to $7.0 million, royalties and a requirement to commence a CD-NP clinical trial within 18 months to retain certain rights.
- There were no material pending legal proceedings or reported material changes in internal control effectiveness. Management concluded disclosure controls were effective at the reasonable assurance level.
Important Facts for Investors to Verify
- Timing, enrollment, safety and efficacy results for the Phase II ALLSTAR trial and the planned DYNAMIC and cenderitide programs.
- Janssen’s option exercise decision, remaining performance obligations and the timing of future collaboration-income recognition.
- Availability and terms of additional financing, including potential equity dilution and the company’s liquidity runway.
- Actual CIRM loan disbursements, milestone compliance, repayment obligations, risk-premium exposure and possible forgiveness.
- Manufacturing capacity, regulatory status, donor-heart supply and third-party manufacturing arrangements.
- Scope and enforceability of licensed and acquired intellectual-property rights, including the Medtronic transfer and its 18-month clinical-trial condition.
- The effect of approximately 5.31 million anti-dilutive options and warrants excluded from diluted loss-per-share calculations.